OncoZenge submits application for PRIME status in the EU
OncoZenge submits application for PRIME status in the EU
Stay updated with breaking news from Stephen Sonis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
OncoZenge submits application for PRIME status in the EU
/PRNewswire/ -- EpicentRx, a leading edge, clinical stage biopharmaceutical company, announced the publication of Phase 2 results of the PREVLAR trial which...
/PRNewswire/ -- EpicentRx, a leading edge, clinical stage biopharmaceutical company, announced the publication of Phase 2 results of the PREVLAR trial which...
Destiny Pharma plc (AIM: DEST), a clinical-stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, today announces that it has started a new research programme. The research study will be conducted in the US by Oral Mucositis (“OM”) expert ...